benzyl 4-(6-oxo-1,6-dihydropyridazin-3-yl)piperazine-1-carboxylate | 1204603-24-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: benzyl 4-(6-oxo-1,6-dihydropyridazin-3-yl)piperazine-1-carboxylate
• 英文别名: benzyl 4-(6-oxo-1H-pyridazin-3-yl)piperazine-1-carboxylate
• CAS: 1204603-24-6
• 化学式: C₁₆H₁₈N₄O₃
• 分子量: 314.344
• InChiKey: ZUSDVNFSUVPFDX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  74.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  benzyl 4-(6-oxo-1,6-dihydropyridazin-3-yl)piperazine-1-carboxylate 在 氢溴酸 、 potassium carbonate 、 溶剂黄146 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 (S)-tert-butyl 2-((4-(1-(4-chloro-2-fluorophenethyl)-6-oxo-1,6-dihydropyridazin-3-yl)piperazin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1h-benzo[d]imidazole-6-carboxylate
  参考文献：
  名称：

  WO2020103815A5

  摘要：

  公开号：

  WO2020103815A5
• 作为产物：
  描述：

  苄基-1-哌嗪碳酸酯 在 sodium acetate 、 溶剂黄146 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 为溶剂， 生成 benzyl 4-(6-oxo-1,6-dihydropyridazin-3-yl)piperazine-1-carboxylate
  参考文献：
  名称：

  WO2020103815A5

  摘要：

  公开号：

  WO2020103815A5

文献信息

• NOVEL 9-SUBSTITUTED-5-CARBOXY-OXADIAZINO-QUINOLONE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ANTI-BACTERIALS
  申请人：Ropp Sandrine

  公开号：US20100009980A1

  公开（公告）日：2010-01-14

  A subject of the invention is the compounds of formula (I): wherein R 1 , R 2 , R 3 , R′ 3 , R 4 , R′ 4 , R 5 , R 6 and R 7 are as described in the application, in the form of enantiomers or mixtures, as well as their salts with acids and bases, their preparation and their application as anti-bacterials, in both human and veterinary medicine.

  本发明涉及以下式（I）的化合物：其中R1、R2、R3、R′3、R4、R′4、R5、R6和R7如申请中所述，以对映体或混合物的形式存在，以及它们与酸和碱的盐，它们的制备以及它们作为抗菌剂在人类和兽医医学中的应用。
• 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials
  申请人：VETOQUINOL S.A.

  公开号：EP2145891A1

  公开（公告）日：2010-01-20

  A subject of the invention is the compounds of formula (I): wherein R1, R2, R3, R'3, R4, R'4, R5, R6 and R7 are as described in the application, in the form of enantiomers or mixtures, as well as their salts with acids and bases, their preparation and their application as anti-bacterials, in both human and veterinary medicine.

  本发明的一个主题是式（I）化合物： 其中 R1、R2、R3、R'3、R4、R'4、R5、R6 和 R7 如本申请所述、 以对映体或混合物的形式存在，以及它们与酸和碱的盐类、它们的制备和它们作为抗菌剂在人类和兽医中的应用。
• GLP-1R agonists and uses thereof
  申请人：QILU REGOR THERAPEUTICS INC.

  公开号：US10844049B2

  公开（公告）日：2020-11-24

  The invention described herein provides compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.

  本发明提供了式（I）化合物及其药物组合物、 用于治疗 2 型糖尿病、糖尿病前期、肥胖症、非酒精性脂肪肝、非酒精性脂肪性肝炎和心血管疾病等。
• 9-SUBSTITUTED-B-CARBOXY-OXADIAZINO-QUINOLONE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ANTI-BACTERIALS
  申请人：VETOQUINOL S.A.

  公开号：EP2310395B1

  公开（公告）日：2012-01-18
• GLP-1R AGONISTS AND USES THEREOF
  申请人：QILU REGOR THERAPEUTICS INC.

  公开号：US20200283424A1

  公开（公告）日：2020-09-10

  The invention described herein provides compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.